PCSK9 and familial hyperaldosteronism: It has been reported that the proportion of patients with FH which could not be explained by LDLR, APOB or PCSK9 mutations was estimated to be 15.25%.26 Patients with clinical phenotype of FH may have negative genetic testing results for the primary genes.